Network-based hub biomarker discovery for glaucoma
Objective Glaucoma is an optic neuropathy and the leading cause of irreversible blindness worldwide. However, the early detection of glaucoma remains challenging, as chronic forms of glaucoma remain largely asymptomatic until considerable irreversible visual field deficits have ensued. Thus, biomark...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-11-01
|
| Series: | BMJ Open Ophthalmology |
| Online Access: | https://bmjophth.bmj.com/content/9/1/e001915.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846168221896409088 |
|---|---|
| author | Lei Zhang Min Li Honghua Yu Mingguang He Xianwen Shang Xiayin Zhang Yu Huang Xueli Zhang Guang Hu Shunming Liu Katerina Kiburg Ke Zhao Shuo Ma Ha Jason |
| author_facet | Lei Zhang Min Li Honghua Yu Mingguang He Xianwen Shang Xiayin Zhang Yu Huang Xueli Zhang Guang Hu Shunming Liu Katerina Kiburg Ke Zhao Shuo Ma Ha Jason |
| author_sort | Lei Zhang |
| collection | DOAJ |
| description | Objective Glaucoma is an optic neuropathy and the leading cause of irreversible blindness worldwide. However, the early detection of glaucoma remains challenging, as chronic forms of glaucoma remain largely asymptomatic until considerable irreversible visual field deficits have ensued. Thus, biomarkers that facilitate early diagnosis and treatment for glaucoma patients with a high risk of progression are pressing.Methods and analysis Human disease–biomarker interactions network and human disease–target–drug interactions network were first constructed based on multiomics data. The greedy search algorithm was used to search for the hub biomarkers and drug targets for glaucoma. Genome-wide association studies and epidemiological data from the UK Biobank were used to verify our results. Biological network and functional analysis was conducted to find common network features and pathways.Results We identified 10 hub biomarkers/drug targets for the diagnosis, treatment and prognosis for glaucoma. These results were verified by text mining and genomic/epidemiology data. We also predicted the new application of BMP1 and MMP9 to diagnose glaucoma and confirm the theory of hub biomarkers with multiple clinical applications. Further, relevant pivotal pathways for these hub biomolecules were discovered, which may serve as foundations for future biomarker and drug target prediction for glaucoma.Conclusion We have used a network-based approach to identify hub diagnostic and therapeutic biomarkers for glaucoma and detected relationships between glaucoma and associated diseases. Several hub biomarkers were identified and verified, which may play more important roles in the diagnosis and treatment of glaucoma. |
| format | Article |
| id | doaj-art-ecf9f66a4524409d993fdd500f2b77a1 |
| institution | Kabale University |
| issn | 2397-3269 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open Ophthalmology |
| spelling | doaj-art-ecf9f66a4524409d993fdd500f2b77a12024-11-14T06:05:08ZengBMJ Publishing GroupBMJ Open Ophthalmology2397-32692024-11-019110.1136/bmjophth-2024-001915Network-based hub biomarker discovery for glaucomaLei Zhang0Min Li1Honghua Yu2Mingguang He3Xianwen Shang4Xiayin Zhang5Yu Huang6Xueli Zhang7Guang Hu8Shunming Liu9Katerina Kiburg10Ke Zhao11Shuo Ma12Ha Jason13School of Translational Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, AustraliaMedical Research Center, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, People`s Republic of ChinaGuangdong Eye Institute, Department of Ophthalmology, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, People`s Republic of ChinaGuangdong Eye Institute, Department of Ophthalmology, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, People`s Republic of ChinaGuangdong Eye Institute, Department of Ophthalmology, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, People`s Republic of ChinaGuangdong Eye Institute, Department of Ophthalmology, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, People`s Republic of ChinaGuangdong Eye Institute, Department of Ophthalmology, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, People`s Republic of ChinaMedical Research Center, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, People`s Republic of ChinaCenter for Systems Biology, Department of Bioinformatics, School of Biology and Basic Medical Sciences, Soochow University, Suzhou, ChinaGuangdong Eye Institute, Department of Ophthalmology, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, People`s Republic of ChinaRoyal Victorian Eye and Ear Hospital, Melbourne, Victoria, AustraliaMedical Research Center, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, People`s Republic of ChinaClinical Data Center, Guangzhou Women and Children`s Medical Center, Guangzhou Medical University, Guangzhou, People`s Republic of ChinaRoyal Victorian Eye and Ear Hospital, Melbourne, Victoria, AustraliaObjective Glaucoma is an optic neuropathy and the leading cause of irreversible blindness worldwide. However, the early detection of glaucoma remains challenging, as chronic forms of glaucoma remain largely asymptomatic until considerable irreversible visual field deficits have ensued. Thus, biomarkers that facilitate early diagnosis and treatment for glaucoma patients with a high risk of progression are pressing.Methods and analysis Human disease–biomarker interactions network and human disease–target–drug interactions network were first constructed based on multiomics data. The greedy search algorithm was used to search for the hub biomarkers and drug targets for glaucoma. Genome-wide association studies and epidemiological data from the UK Biobank were used to verify our results. Biological network and functional analysis was conducted to find common network features and pathways.Results We identified 10 hub biomarkers/drug targets for the diagnosis, treatment and prognosis for glaucoma. These results were verified by text mining and genomic/epidemiology data. We also predicted the new application of BMP1 and MMP9 to diagnose glaucoma and confirm the theory of hub biomarkers with multiple clinical applications. Further, relevant pivotal pathways for these hub biomolecules were discovered, which may serve as foundations for future biomarker and drug target prediction for glaucoma.Conclusion We have used a network-based approach to identify hub diagnostic and therapeutic biomarkers for glaucoma and detected relationships between glaucoma and associated diseases. Several hub biomarkers were identified and verified, which may play more important roles in the diagnosis and treatment of glaucoma.https://bmjophth.bmj.com/content/9/1/e001915.full |
| spellingShingle | Lei Zhang Min Li Honghua Yu Mingguang He Xianwen Shang Xiayin Zhang Yu Huang Xueli Zhang Guang Hu Shunming Liu Katerina Kiburg Ke Zhao Shuo Ma Ha Jason Network-based hub biomarker discovery for glaucoma BMJ Open Ophthalmology |
| title | Network-based hub biomarker discovery for glaucoma |
| title_full | Network-based hub biomarker discovery for glaucoma |
| title_fullStr | Network-based hub biomarker discovery for glaucoma |
| title_full_unstemmed | Network-based hub biomarker discovery for glaucoma |
| title_short | Network-based hub biomarker discovery for glaucoma |
| title_sort | network based hub biomarker discovery for glaucoma |
| url | https://bmjophth.bmj.com/content/9/1/e001915.full |
| work_keys_str_mv | AT leizhang networkbasedhubbiomarkerdiscoveryforglaucoma AT minli networkbasedhubbiomarkerdiscoveryforglaucoma AT honghuayu networkbasedhubbiomarkerdiscoveryforglaucoma AT mingguanghe networkbasedhubbiomarkerdiscoveryforglaucoma AT xianwenshang networkbasedhubbiomarkerdiscoveryforglaucoma AT xiayinzhang networkbasedhubbiomarkerdiscoveryforglaucoma AT yuhuang networkbasedhubbiomarkerdiscoveryforglaucoma AT xuelizhang networkbasedhubbiomarkerdiscoveryforglaucoma AT guanghu networkbasedhubbiomarkerdiscoveryforglaucoma AT shunmingliu networkbasedhubbiomarkerdiscoveryforglaucoma AT katerinakiburg networkbasedhubbiomarkerdiscoveryforglaucoma AT kezhao networkbasedhubbiomarkerdiscoveryforglaucoma AT shuoma networkbasedhubbiomarkerdiscoveryforglaucoma AT hajason networkbasedhubbiomarkerdiscoveryforglaucoma |